Anticonvulsant Pharmacogenetic Test: HLA, CYP2C9, CYP2C19, and Results
An anticonvulsant pharmacogenetic test looks for inherited variants that can affect the safety or handling of certain antiseizure medicines. The most clinically established findings...
BCHE Genetic Test: Pseudocholinesterase Deficiency, Anesthesia Risk, and Results
A BCHE genetic test looks for inherited changes that reduce the activity of butyrylcholinesterase, an enzyme also called pseudocholinesterase or plasma cholinesterase. Low or...
CACNA1S Genetic Test: Malignant Hyperthermia Risk and Results
A CACNA1S genetic test looks for variants in a skeletal-muscle calcium-channel gene that can contribute to malignant hyperthermia susceptibility. Malignant hyperthermia is not an...
Chemotherapy Pharmacogenetic Test: DPYD, UGT1A1, TPMT, and Results
A chemotherapy pharmacogenetic test can identify inherited differences that affect how a patient handles particular anticancer drugs, but no single result predicts response to...
COMT Genetic Test: Dopamine Metabolism, Pain, Medication Response, and Results
A COMT genetic test usually examines rs4680, also called Val158Met, a common variant that changes the activity of catechol-O-methyltransferase. This enzyme helps inactivate dopamine,...
CYP1A2 Genetic Test: Caffeine, Clozapine, Drug Metabolism, and Results
A CYP1A2 genetic test examines variants in an enzyme that metabolizes caffeine and several medicines, including clozapine, olanzapine, theophylline, tizanidine, and duloxetine. Commercial reports...
CYP2B6 Genetic Test: Efavirenz, Methadone, Bupropion, and Results
A CYP2B6 genetic test estimates inherited differences in an enzyme that metabolizes efavirenz, methadone, bupropion, and several other drugs. The result can be clinically...
CYP2C9 Genetic Test: Warfarin, NSAIDs, Phenytoin, and Results
A CYP2C9 genetic test predicts how efficiently the CYP2C9 enzyme clears several medicines, including warfarin, selected nonsteroidal anti-inflammatory drugs, and phenytoin. Reduced-function variants can...
CYP2C19 Clopidogrel Genetic Test: Plavix Response, Heart Risk, and Results
A CYP2C19 clopidogrel genetic test estimates whether a patient can efficiently convert Plavix into its active antiplatelet metabolite. Clopidogrel is a prodrug, so inherited...
CYP2C19 Genetic Test: Clopidogrel, Antidepressants, PPIs, and Results
A CYP2C19 genetic test estimates how actively your body makes the CYP2C19 enzyme, which helps process several widely used medicines. The same result can...
CYP2D6 and CYP2C19 Antidepressant Pharmacogenetic Test: SSRI Response and Results
A CYP2D6 and CYP2C19 antidepressant pharmacogenetic test estimates how quickly a person may process selected antidepressants. It can help explain unusually high exposure, early...
CYP2D6 Genetic Test: Drug Metabolism, Poor Metabolizer, and Results
A CYP2D6 genetic test predicts how much functional CYP2D6 enzyme a person is likely to produce. This enzyme affects many antidepressants, opioids, antipsychotics, attention-deficit...
CYP2D6 Opioid Pharmacogenetic Test: Codeine, Tramadol, Oxycodone, and Results
A CYP2D6 opioid pharmacogenetic test predicts how efficiently the body converts certain opioids into more active metabolites. The result is most clinically useful for...
CYP3A4 Genetic Test: Drug Metabolism, Variants, and Results
A CYP3A4 genetic test looks for inherited variants that may change the activity of CYP3A4, a liver and intestinal enzyme involved in processing many...
CYP3A5 Genetic Test: Tacrolimus Dosing, Metabolism, and Results
A CYP3A5 genetic test predicts how strongly a person expresses the CYP3A5 enzyme, one of the main pathways that clears tacrolimus. People who express...
DPYD Genetic Test: Fluoropyrimidine Toxicity, 5-FU, Capecitabine, and Results
A DPYD genetic test identifies inherited variants that can reduce dihydropyrimidine dehydrogenase, or DPD, the main enzyme that breaks down fluorouracil. Reduced DPD activity...
Fluoropyrimidine Pharmacogenetic Test: DPYD, 5-FU, Capecitabine Toxicity, and Results
A fluoropyrimidine pharmacogenetic test is a pre-treatment safety assessment for people who may receive intravenous 5-fluorouracil or oral capecitabine. It usually examines DPYD, the...
G6PD Genetic Test: Medication Hemolysis Risk, Deficiency, and Results
A G6PD genetic test looks for inherited changes in the glucose-6-phosphate dehydrogenase gene that can make red blood cells unusually vulnerable to oxidative stress....
HLA-A*31:01 Genetic Test: Carbamazepine Hypersensitivity Risk and Results
An HLA-A31:01 genetic test estimates whether a person has a higher-than-average risk of immune-mediated hypersensitivity from carbamazepine. The allele is associated with several reaction...
HLA-B*15:02 Genetic Test: Carbamazepine Skin Reaction Risk and Results
The HLA-B15:02 genetic test is used to reduce the risk of Stevens–Johnson syndrome and toxic epidermal necrolysis before carbamazepine or certain related antiseizure medicines...